Xeris Biopharma raises FY23 revenue view to $145M-$165M from $135M-$165M

Consensus $149.35M. “We posted another record quarter of revenue due to the continued strong demand of all three products, as well as contributions from our partnerships,” said Paul Edick, chairman and CEO of Xeris Biopharma. “Our differentiated business model, exceptional year-to-date performance, and expectations for the remainder of the year gives us the confidence to tighten our 2023 guidance by raising the low end of the total revenue range to $145 to $165 million from $135 to $165 million; reducing cash utilization range to $57 to $67 million from $57 to $77 million; improving year-end cash range to $55 to $65 million. And, we expect to be at the cash flow breakeven point in the fourth quarter and continue being a self-sustaining enterprise.”